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Abstract Rearrangements in the distal region of the
short arm of chromosome 1 are recurrent aberrations in
a broad spectrum of human neoplasias. However, nei-
ther the location of the breakpoints (BP) on 1p36 nor the
candidate genes have been fully determined. We have
characterized, by ﬂuorescence in situ hybridization
(FISH), the BP in 26 patients with hematological neo-
plasias and 1p36 rearrangements in the G-banding kar-
yotype. FISH allowed a better characterization of all
samples analyzed. Nine cases (35%) showed reciprocal
translocations, 15 (58%) unbalanced rearrangements,
and two (7%) deletions. We describe two new recurrent
aberrations. In 18 of the 26 cases analyzed the BP were
located in band 1p36, which is 25.5 Mb long. In 14 of
these 18 cases (78%) and without distinction between
myeloid and lymphoid neoplasias, the BP clustered in a
2.5 Mb region located between 1p36.32 and the telo-
mere. Interestingly, this region is contained in the
10.5 Mb cluster on 1p36.22-1pter deﬁned in cases with
1p36 deletion syndrome. The 2.5 Mb region, located on
1p36.32-1pter, has a higher frequency of occurrence of
tandem repeats and segmental duplications larger than
1 kb, when compared with the 25.5 Mb of the complete
1p36 band. This could explain its proneness for
involvement in chromosomal rearrangements in hema-
tological neoplasias.
Introduction
Cytogenetic analysis of various types of human malig-
nancies, ranging from virtually all types of solid tumors,
to leukemias and myeloproliferative disorders, have
shown the non-random involvement of abnormalities of
chromosome 1p36 (Atkin 1986; Dave et al. 1995; Weith
et al. 1996; Mitelman et al. 1997). However, the location
of the breakpoints (BP) on 1p36 and the candidate genes
involved have not been fully determined (Johansson
et al. 1999; Rowley 1999; Mitelman 2000). The aﬀected
regions frequently span many megabases of DNA,
hampering the identiﬁcation of critical genes (Boei et al.
1998; Schutte et al. 2001). Moreover, a decreased dis-
ease-free survival and a shorter overall survival have
been correlated with breaks in the 1p32–p36 region
(Levine et al. 1988; Oﬃt et al. 1991).
Deletions of the short arm of chromosome 1 (1p36)
are present in approximately 30% of neuroblastoma
(NB) cases, the most common malignant solid childhood
tumor derived from the neural crest (Brodeur et al. 1977;
Gilbert et al. 1982; Weith et al. 1989). The biological
signiﬁcance of 1p loss has been indicated by an inter-
esting experiment: Bader et al. (1991) transferred normal
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1p material into a NB cell line carrying a 1p deletion and
found suppression of tumorigenicity with induction of
cell diﬀerentiation (Bader et al. 1991). Deletions of 1p
are poor prognosis factors in NB (Caron et al. 1996;
Maris et al. 2000).
In hematological neoplasias, the most frequent
abnormalities involving 1p36 are unbalanced translo-
cations, presented as add(1)(p36) at the karyotype level,
in both myeloid and lymphoid neoplasias (Mitelman
et al. 2003). Nine recurrent balanced rearrangements
have been reported involving band 1p36 in hemato-
logical neoplasias, the most frequent being
t(1;3)(p36;q21), which shares, with 3q21q26 syndrome,
its association with myeloid malignancies and, in some
cases, similar clinicopathological features (Shimizu
et al. 2000; Mitelman et al. 2003; Lahortiga et al. 2004).
Moreover, loss of heterozygosity (LOH) of the 1p36
region has been reported in 47% of the patients with
chronic myelocytic leukemia (CML) in transformation,
in 30% of the patients with progression of myelodys-
plastic syndrome (MDS) to acute myeloid leukemia
(AML), and in 13% of patients with MDS (Mori et al.
1998, 2003; Hofmann et al. 2001). All these studies
have contributed to the deﬁnition of the smallest region
of overlap (SRO) located on 1p36, suggesting the
location, in this region, of candidate genes involved in
the malignant proliferation of myeloid precursor cells
(Hofmann et al. 2001). Region 1p36 contains several
genes that are involved in the regulation of cell pro-
liferation and diﬀerentiation, including several genes
coding for hematopoietic growth factor receptors, and
that could be considered candidate genes (Hofmann
et al. 2001). Characterization of the BP could help to
identify genes with important roles in cancer develop-
ment and contribute to the development of tailored
treatment (Varga et al. 2001).
We report the characterization, by ﬂuorescence in situ
hybridization (FISH), of the BP in 26 patients with
hematological neoplasias and 1p36 rearrangements. This
analysis has allowed us to deﬁne a region of 2.5 Mb that
is located between 1p36.32 and the telomere, a region in
which the BP of 78% of cases with a BP located in band
1p36 are clustered. This region shows characteristics,
such as the presence of genomic repeats, that could ex-
plain its proneness for involvement in chromosomal
rearrangements.
Materials and methods
Patients
Twenty-six patients with hematological neoplasias and
1p36 rearrangements at the G-band level analyzed at the
University of Navarra and at the University of Salam-
anca (Spain) were included. Of these, 16 patients had
myeloid neoplasias, and 10 had lymphoid neoplasias: ﬁve
AML, eight MDS, three myeloproliferative disorders
(MPD), four ALL, two multiple myeloma (MM) and
four NHL. Genetic characterization is included in Ta-
ble 1. All samples were obtained with informed consent.
G-banding karyotype
Cytogenetic studies were performed on unstimulated
short-term bone marrow cultures. G-banded karyotypes
are shown in Table 1 (described according to ISCN
1995, see Mitelman 1995).
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) studies were
performed with 51 bacterial artiﬁcial chromosomes
(BACs) and P1 artiﬁcial chromosomes (PACs) located
between 1p32.3 and 1p36.33 (Fig. 1). Sixty-ﬁve BAC
and PAC clones were also used to characterize the BP in
the partner chromosomes and in other rearrangements
found in the karyotypes. All the clones were designed
according to the current mapping data and were ob-
tained from libraries from the Roswell Park Cancer
Institute (Buﬀalo, N.Y.). The DNA from clones was
extracted by using the Qiaprep Spin Miniprep kit
(Qiagen, Hilden, Germany). Probes were labeled with
Spectrum Green and Spectrum Orange (Vysis, Downers
Grove, Ill., USA) by nick translation and were used
pair-wise. Commercial probes employed were: TelVy-
sion 1p, LSI TEL/AML1 ES, LSI CBFB dual colour
rearrangement probe, LSI BCR/ABL ES, LSI IgH/
CCDN1, LSI IgH/BCL2, LSI MLL dual colour rear-
rangement probe, and WCP for chromosomes 1, 4, 6, 8,
and 13 (Vysis). FISH analysis was performed on bone
marrow samples as previously described (Odero et al.
2001).
Spectral karyotyping analysis
The SkyPaint DNA kit for spectral karyotyping (SKY)
and the hybridization reagents were obtained from Ap-
plied Spectral Imaging (Mannheim, Germany). Slides
for spectral karyotyping were hybridized with the probe
cocktail following the manufacture’s protocol.
Bioinformatic analysis
The DNA sequences and their annotations were retrieved
from the EnsEMBL Genome Browser Databases, mak-
ing use of the EnsEMBL Perl Application Programming
Interface (Hubbard et al. 2002). Pattern ﬁnding was
carried out by using the fuzznuc program from the
European Molecular Biology Open Software Suite (Rice
et al. 2000). Segmental Duplications were computed from
tables that are available at the University of Santa Cruz
Genome Browser (http://genome.ucsc.edu/, version
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hg15, April 2003) and that make use of data in Bailey
et al. (2001). Statistical analysis was performed with R (R
Foundation for Statistical Computing, Austria).
Results
We have characterized, by FISH, the BP in bone
marrow samples from 26 patients with hematological
neoplasias and 1p36 rearrangements at the G-banding
level. Nineteen cases had a complex karyotype, with
more than three unrelated aberrations. Nine cases
showed reciprocal translocations, and 15 had unbal-
anced translocations, three of them being recurrent and
with complex rearrangements. One of the cases with an
unbalanced rearrangement (case 18) had another clone
with a terminal deletion. In addition, two cases showed
a terminal deletion involving the same region. Revised
karyotypes of the patients after FISH analysis are gi-
ven in Table 1. A diagram of the rearrangements found
in the 1pter-1p32.3 region is shown in Fig. 1. All cases
were further characterized. During the study, the rela-
tive location for each clone used was adjusted on the
basis of new sequencing information becoming avail-
able. The characterization of each case allowed the
classiﬁcation of the rearrangements into reciprocal
translocations, unbalanced rearrangements, or terminal
deletions.
Reciprocal translocations
Nine cases had reciprocal translocations (Table 1, Fig-
s. 1a, 2a, b). The chromosome regions involved in the
translocations with 1p were 2p, 3q (two cases), 5q, 6p,
6q, 9q, 12p, and 21q. Two of these cases (6 and 13) have
been previously reported (Odero et al. 2002; Lahortiga
et al. 2004).
Unbalanced translocations
Fifteen cases had unbalanced translocations, and in this
group, three recurrences could be determined (Table 1,
Figs. 1b, 2c–h). Cases 2 and 3, both with a diagnosis of
AML M3, showed (at the G-banding level) a chromo-
some 1 with unidentiﬁed genetic material that was in-
serted at 1p36, and that FISH analysis with a
chromosome 1 paint probe identiﬁed as a duplicated
Fig. 1 Rearrangements with FISH results. Left An integrated map
of the 1pter-1p32.3 region including the physical positions (in Mb)
and locations of the clones used in this study (brackets GenBank
accession number) and the candidate genes in cancer reported in
the literature. Vertical bars Rearrangements found for each case
distributed in balanced translocations (a), unbalanced rearrange-
ments (b), and terminal deletions (c), black bars chromosome 1
regions, striped gray bars chromosome 1 deletions, striped black
bars regions found to be duplicated or ampliﬁed, dotted bars
regions where no FISH is data available, white bars regions
translocated to a derivative chromosome listed within the circle at
the telomeric end, black boxes cases with a BP located in the 2.5-
Mb cluster
479
region of chromosome 1 inserted between the two clones
RP1-283E3 and PR5-890O3. However, no more mate-
rial was available for further analysis.
In six patients, FISH detected either duplications
(cases 4, 10, 11, and 26) or ampliﬁcations (cases 9 and
12) of 1p probes (Fig. 2c–e). Interestingly, in cases 11
and 12, both with a diagnosis of MDS, the same region
located between 1p34.1 (43.0 Mb) and 1p32.3 (50.7 Mb)
was duplicated in case 11 and ampliﬁed in case 12. Case
4 showed a highly complex translocation involving
chromosomes 1, 6, and 12, with some regions being
duplicated. There was a duplication in the der(1), from
1p32.3 to 1p34.2, and another duplication in chromo-
some 6, from 6p21.1 to 6p24.1. Therefore, a three-way
translocation could have taken place among chromo-
somes 1p34.1, 6p21.1, and 12p13 (Fig. 2e). In case 26,
the G-banding karyotype suggested that the 1p region
was duplicated, but this could not be conﬁrmed by FISH
because of lack of material. Case 15 showed a complex
translocation between chromosomes 1 and 6, with the
presence of interstitial deleted regions (Fig. 2f).
Another recurrence was found in cases 19, 23, and 24:
the duplication of 1q21 and the formation of an
unbalanced translocation der(1)t(1;1)(p36;q21). How-
ever, the three cases showed diﬀerences regarding the
presence or absence of a deletion in the 1p36 region and
in its length: only case 24 had a terminal deletion,
whereas case 19 did not have a terminal deletion, con-
ﬁrmed by the presence of the subtelomeric 1p region on
the 1qter, and case 23 had the unbalanced translocation
with no deletion of the 1p36 region (Fig. 2g).
Terminal deletions
Cases 8 and 17 had the same terminal deletion
del(1)(p34.3) (Fig. 1c). Moreover, case 18 had a second
clone with a chromosome der(1) that carried a terminal
deletion on both the p and q arms (Fig. 2h).
Bioinformatic analysis
In 18 of the 26 cases analyzed, BP were located in band
1p36, which extends for 25.5 Mb. In 14 of these cases
(77.8%, 14/18), eight with myeloid and six with lym-
phoid neoplasias, the BP clustered in a 2.5-Mb region
located between 1p36.32 and the telomere (Fig. 1).
Comparison by bioinformatics analysis of the most
telomeric 2.5 Mb region, in which the BP of our patients
cluster, and of the complete 1p36 band showed that the
2.5 Mb region has distinctive characteristics that could
account for the large number of chromosomal rear-
rangements found. This 2.5 Mb region was richer in
tandem and inverted repeats detected by the program
TRF, as annotated in Ensemble (Benson 1999). The
local percentage of sequence covered by these repeats,
considering contiguous windows of 100 kb of genomic
DNA, reached values as high as 20%, whereas analo-
gous measurements for nearby sequences located in the
rest of the 1p36 band were around 5%. We also
observed a statistically signiﬁcant larger number of
segmental duplications in this 2.5 Mb region. As shown
in Table 2, we computed the total number of duplicons
larger than 1 kb in the most telomeric cytogenetic band
of the short arm of each chromosome. Region 1p36 did
not show diﬀerences in comparison with the rest of the
bands analyzed. However, the 2.5 Mb region, in which
the BP in our patients clustered, spanned the most
telomeric sub-band within 1p36 (i.e. 1p36.33). There-
fore, we computed the number of segmental duplications
present at the most telomeric sub-band of each chro-
mosome. As shown in Table 2, the percentage of seg-
mental duplications per megabase is signiﬁcantly higher
in 1p36.33 than in the rest of the short arms.
Discussion
FISH analysis of 26 samples of patients with hemato-
logical neoplasias and 1p36 rearrangements in the G-
banding karyotype has allowed us to deﬁne a 2.5Mb
region located between 1p36.32 and the telomere, a re-
gion in which the BP of 78% of cases with a BP located
in the band 1p36 cluster. There was no distinction be-
tween myeloid and lymphoid neoplasias. In our search
for sequence elements that might account for the in-
creased frequency of BP in the most telomeric 2.5 Mb of
1p36, we have found that this region is richer in tandem
repeats and, most notably, is particularly rich in seg-
mental duplications larger than 1 kb. Segmental dupli-
cations are known to be involved in chromosomal
rearrangements responsible for human disease and have
been recently shown to mediate the genesis of recurrent
chromosomal translocations, such as t(9;22)(q34;q11)
involving BCR and ABL or t(12;15)(p13;q25) involving
ETV6 and NTRK3 (Ji et al. 2000; Osborne et al. 2001;
Pujana et al. 2001; Saglio et al. 2002). In this regard, it is
interesting to note that this feature is circumscribed to
1p36.33, which constitutes most of the 2.5 Mb region
frequently rearranged in our samples, whereas the whole
of 1p36 is not diﬀerent from other telomeric bands.
Thus, the particular enrichment of this region in seg-
mental duplications might explain why so many BP are
clustered here.
Interestingly, this 2.5 Mb region is contained in the
10.5 Mb cluster on 1p36.22-1pter deﬁned in cases with
1p36 deletion syndrome. Monosomy 1p36 is the most
Fig. 2 FISH analysis of some of the cases studied with probes for
chromosome 1. a FISH analysis of case 5 with BAC 333E3. b FISH
analysis of case 6 with BAC 519D12. c FISH analysis of case 9 with
BAC 740P5 and PAC 1092A11. dFISHanalysis of case 10with BAC
740P5 and PAC 163G9. e, f Representation of FISH results from
cases 4 and 15, respectively. gAnalysis of cases 19, 23 and 24: partial
G-banding of chromosomes 1 (I), representation of FISH results (II),
and FISH analysis with probes from 1q (III). h SKY analysis of the
two clones detected in case 18
c
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common congenital terminal deletion syndrome. Pa-
tients present multiple anomalies and mental retardation
(Shapira et al. 1997; Shaﬀer et al. 2001). Heilstedt et al.
(2003) have constructed a contig of overlapping large
insert clones from the most distal 10.5 Mb of 1p36
(Fig. 3a) to evaluate the deletion sizes in various patients
with 1p36 syndrome and have narrowed the BP region
to 0.5 Mb bins (Heilstedt et al. 2003). Deletion sizes
range widely, but most BP (12.5%) cluster 4.0–4.5 Mb
from the telomere. Our BP clusters in the ﬁrst 2.5 Mb
and is included in the 10.5 Mb region deﬁned for 1p36
deletion syndrome, although none of our BP are located
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in the most frequent 0.5 Mb (4.0–4.5 Mb) region deﬁned
by Heilstedt et al. (2003). The mechanism involved in
deletions is frequently associated with duplications
aﬀecting the region. Therefore, the high frequency of
duplications detected in our series by bioinformatic
analysis of the 1p36 region might explain the high inci-
dence of deletions in 1p36 deletion syndrome.
Several studies have focused on the deﬁnition of the
SRO in diverse neoplasias in order to determine candi-
date oncogenes and/or tumor suppressor genes (TSGs)
that could explain the proneness of the 1p36 region for
involvement in chromosomal rearrangements. Our de-
ﬁned region of 2.5 Mb partially overlaps with the SRO
on 1p36 reported for disorders such as NB or MDS in
transformation (Fig. 3).
LOH has been widely studied in NB. The 2.5 Mb
region deﬁned in our patients partially overlaps with the
consensus SRO for NB deﬁned by Cheng et al. (1995)
and Martinsson et al. (1995) (Fig. 3b, I). This region was
further reﬁned ﬁrst by White et al. (1995; Fig. 3b, II) and
later by Bauer et al. (2001; Fig. 3b, III). These reﬁned
regions show no overlap with our 2.5 Mb region; how-
ever, a study with an larger number of patients with NB
(205 patients) has reported two SRO in which two
suppressor loci involved in the pathogenesis of NB may
be located; both regions include the 2.5 Mb region de-
ﬁned in our patients (Fig. 3b, IV-1, IV-2; Caron et al.
2001).
The 2.5 Mb region is contained in the most distal
SRO of the two deﬁned by Mori et al.(2003) for patients
with MDS in transformation (Fig. 3 c-I, c-II). Mori
et al. (1998, 2003) have suggested that putative TSGs
that frequently play an important role in the evolution
to blast crisis and in the progression of MDS to AML
may reside in this region. Our region shows no over-
lapping with the SRO deﬁned by LOH analysis in CML
in transformation (Fig. 3 d; Mori et al. 1998), or in
patients with MDS (Fig. 3 e; Hofmann et al. 2001).
Diﬀerences from our series could be attributable to the
diﬀerent techniques used in the analysis. Moreover, the
most telomeric microsatellite sequence included in both
studies was D1S243 located at 2.1 Mb and was deleted
in 63% and 20% of the patients with an informative loci,
in CML and MDS, respectively (Mori et al. 1998;
Hofmann et al. 2001); therefore, many of the patients
included in these studies could have deletions in the
2.5 Mb region deﬁned in our study.
This delimited region could be helpful for the search
for putative candidate genes involved in hematological
neoplasias. Some of these genes are located in the inte-
grated 1p36 map in Fig. 1 (Mori et al. 1998; Spieker
et al. 2001; Mori et al. 2003). Among these, CDC2L1,
which codes a protein kinase implicated in apoptotic
signaling, is located extremely distally and is hence most
likely to be disrupted (Dave et al. 1999). A deletion of
this gene locus has been observed in 88.5% of NHL
cases containing 1p36 abnormalities, although the
functional role of deletions of CDC2L1 in NHL is still
under consideration (Dave et al. 1999). TP73 has also
been considered a strong candidate TSG. TP73 protein
has a structural and functional homology to TP53,
including the ability to promote apoptosis when over-
expressed in vitro and to up-regulate TP53-responsive
genes involved in cell-cycle control, such as CDKN1A
(Jost et al. 1997; Inokuchi et al. 2001).
Furthermore, three recurrences could be established
after FISH analysis. To our knowledge, two of them
have never been reported before: a der(1)ins(1;1)
(p36.33;?) in two cases with AML-M3, and the dupli-
cation/ampliﬁcation of the 1p32.3–p34.1 region in two
cases with MDS. Moreover, two cases with NHL (cases
23 and 24) and one with ALL-L3 (case 19) showed a
Table 2 Total number of segmental duplication (Dups) per megabase (Mb) in the most telomeric cytogenetic bands and sub-bands of the
short arm of all chromosomes
Band Size (Mb) Dups Dups/Mb Sub-band Size (Mb) Dups Dups/Mb
1p36 27.5 953.0 34.7 1p36.33 2.5 516.0 206.4
2p25 12.0 79.0 6.6 2p25.3 4.0 42.0 10.5
3p26 8.2 20.0 2.4 3p26.3 2.8 15.0 5.4
4p16 11.0 631.0 57.4 4p16.3 4.5 284.0 63.1
5p15 18.4 251.0 13.6 5p15.33 4.5 104.0 23.1
6p25 7.0 145.0 20.7 6p25.3 2.3 76.0 33.0
7p22 6.9 471.0 68.3 7p22.3 2.6 113.0 43.5
8p23 12.5 891.0 71.3 8p23.3 2.3 130.0 56.5
9p24 9.0 125.0 13.9 9p24.3 2.2 42.0 19.1
10p15 6.8 62.0 9.1 10p15.3 3.1 48.0 15.5
11p15 21.7 475.0 21.9 11p15.5 2.8 123.0 43.9
12p13 14.7 374.0 25.4 12p13.33 3.1 15.0 4.8
16p13 16.7 658.0 39.4 16p13.3 6.4 199.0 31.1
17p13 10.7 124.0 11.6 17p13.3 3.1 78.0 25.2
18p11 15.3 477.0 31.2 18p11.32 2.9 71.0 24.5
19p13 23.3 475.0 20.4 19p13.3 6.9 184.0 26.7
20p13 5.0 12.0 2.4 20p13 5.0 12.0 2.4
Mean 26.5 mean 37.3
Mean + 3 SD 91.2 Mean + 3 SD 178.1
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der(1)t(1;1)(p36.33;q21). Lestou et al.(2003) have re-
ported the characterization, by FISH, of this recurrent
translocation in NHL. The formation of this transloca-
tion includes the deletion of 1p36 and the duplication of
1q21 and is considered to be a non-random event in
Fig. 3 Comparison of 1p SRO among various human cancers and
in 1p36 deletion syndrome. Left An integrated map of the 1pter-
1p34.2 region, including the physical position (in Mb), the location
of candidate cancer genes reported in the literature, and the
locations of the markers used in several studies (vertical bars right
extent of SRO)
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NHL, suggesting that a deletion-duplication mechanism
is involved in lymphoma progression (Lestou et al.
2003). Therefore, the high frequency of duplications
detected in our series by bioinformatic analysis in the
2.5 Mb region might explain this mechanism. However,
only case 24 has a true terminal deletion similar to those
described by Lestou et al. (2003). All three cases showed
duplication of the 1q21 region. Although the probes that
we have used for the 1q region are diﬀerent from those
used by Lestou et al. (2003), the duplicated region seems
to be the same (Fig. 2g; Lestou et al. 2003).
In conclusion, the characterization by FISH of 26
patients with hematological neoplasias and 1p36 rear-
rangements has allowed us to deﬁne a 2.5 Mb cluster
region on 1p36.32, a region in which the BP of 78% of
the cases analyzed (both myeloid and lymphoid) are
located. This region, included in the 10.5 Mb minimal
region deleted in 1p36 deletion syndrome, shows char-
acteristics, such as the presence of genomic repeats, that
could explain its proneness for involvement in chromo-
somal rearrangements.
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